Literature DB >> 33710504

Expression and Role of CFTR in Human Esophageal Squamous Cell Carcinoma.

Yoshihisa Matsumoto1, Atsushi Shiozaki2, Toshiyuki Kosuga1, Michihiro Kudou1, Hiroki Shimizu1, Tomohiro Arita1, Hirotaka Konishi1, Shuhei Komatsu1, Takeshi Kubota1, Hitoshi Fujiwara1, Kazuma Okamoto1, Mitsuo Kishimoto3, Eiichi Konishi3, Eigo Otsuji1.   

Abstract

BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent chloride (Cl-) anion conducting channel, and its role in esophageal squamous cell carcinoma (ESCC) was examined in the present study.
METHODS: Overexpression experiments were conducted on human ESCC cell lines following the transfection of a CFTR plasmid, and changes in cell proliferation, the cell cycle, apoptosis, migration, and invasion were assessed. A microarray analysis was performed to examine gene expression profiles. Fifty-three primary tumor samples collected from ESCC patients during esophagectomy were subjected to an immunohistochemical analysis.
RESULTS: Transfection of the CFTR plasmid into the ESCC KYSE 170 and KYSE 70 cell lines suppressed cell proliferation, migration, and invasion and induced apoptosis. The microarray analysis showed the up-regulated expression of genes involved in the p38 signaling pathway in CFTR plasmid-transfected KYSE 170 cells. Immunohistochemical staining revealed a relationship between the CFTR expression pattern at the invasive front and the pN category. A relationship was also observed between the weak expression of CFTR at the invasive front and a shorter postoperative survival in a prognostic analysis.
CONCLUSIONS: The overexpression of CFTR in ESCC activated the p38 signaling pathway and was associated with a good patient prognosis. These results indicate the potential of CFTR as a mediator of and/or a biomarker for ESCC.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33710504     DOI: 10.1245/s10434-021-09752-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.

Authors:  Akihiro Yamada; Yuga Komaki; Fukiko Komaki; Dejan Micic; Samantha Zullow; Atsushi Sakuraba
Journal:  Lancet Oncol       Date:  2018-04-26       Impact factor: 41.316

2.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma.

Authors:  Robert R McWilliams; Gloria M Petersen; Kari G Rabe; Leonard M Holtegaard; Pamela J Lynch; Michele D Bishop; W Edward Highsmith
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

3.  Overexpression of cystic fibrosis transmembrane conductance regulator (CFTR) is associated with human cervical cancer malignancy, progression and prognosis.

Authors:  Xue Peng; Zhao Wu; Lei Yu; Jinke Li; Wenming Xu; Hsiao Chang Chan; Yi Zhang; Lina Hu
Journal:  Gynecol Oncol       Date:  2012-02-21       Impact factor: 5.482

4.  CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Authors:  B L N Than; J F Linnekamp; T K Starr; D A Largaespada; A Rod; Y Zhang; V Bruner; J Abrahante; A Schumann; T Luczak; A Niemczyk; M G O'Sullivan; J P Medema; R J A Fijneman; G A Meijer; E Van den Broek; C A Hodges; P M Scott; L Vermeulen; R T Cormier
Journal:  Oncogene       Date:  2016-01-11       Impact factor: 9.867

5.  Clinical significance of RacGAP1 expression at the invasive front of gastric cancer.

Authors:  Susumu Saigusa; Koji Tanaka; Yasuhiko Mohri; Masaki Ohi; Tadanobu Shimura; Takahito Kitajima; Satoru Kondo; Yoshinaga Okugawa; Yuji Toiyama; Yasuhiro Inoue; Masato Kusunoki
Journal:  Gastric Cancer       Date:  2014-03-11       Impact factor: 7.370

6.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

7.  Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  C E Bear; C H Li; N Kartner; R J Bridges; T J Jensen; M Ramjeesingh; J R Riordan
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

Review 8.  CFTR is a conductance regulator as well as a chloride channel.

Authors:  E M Schwiebert; D J Benos; M E Egan; M J Stutts; W B Guggino
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

Review 9.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

10.  Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV.

Authors:  I S Rodrigues; A M Lavorato-Rocha; B de M Maia; M M A Stiepcich; F M de Carvalho; G Baiocchi; F A Soares; R M Rocha
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

View more
  3 in total

Review 1.  CFTR and Gastrointestinal Cancers: An Update.

Authors:  Rahul Bhattacharya; Zachary Blankenheim; Patricia M Scott; Robert T Cormier
Journal:  J Pers Med       Date:  2022-05-25

2.  Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma: Bioinformatics-driven prognostic value.

Authors:  Xiangtong Meng; Shen Dong; Liu Yangyang; Song Wang; Xiaohao Xu; Tiejun Liu; Xiong Zhuang
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

Review 3.  Revisiting CFTR Interactions: Old Partners and New Players.

Authors:  Carlos M Farinha; Martina Gentzsch
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.